Allergan Q3 net revenues $3.6 billionStaff Writer | November 3, 2016
Allergan reported its third quarter 2016 continuing operations performance.
Allergan A four percent increase
Those were driven by strong performance from key brands and new product launches, offset by the loss of ASACO® HD exclusivity, lower revenues for NAMENDA XRand IR, a decline in non-promoted Established Brands revenues and unfavorable foreign exchange impact.
GAAP operating loss from continuing operations in the third quarter 2016 was $266 million. Non-GAAP adjusted operating income from continuing operations in the third quarter 2016 was $1.78 billion.
For the third quarter 2016, Non-GAAP adjusted EBITDA from continuing operations was $1.9 billion, compared to $2.0 billion for the third quarter 2015.
The decrease was primarily due to higher research and development and selling and marketing costs.
Allergan reported negative cash flow from operations of $1.1 billion for the third quarter of 2016 which was unfavorably impacted by the $2.6 billion current period payment of taxes related to the divestiture of Allergan's Generics business to Teva. ■